Haplo-HSCT for Myelofibrosis

Launched by PEKING UNIVERSITY PEOPLE'S HOSPITAL · Nov 3, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for myelofibrosis (MF), a serious blood condition that can lead to bone marrow failure and an increased risk of leukemia. While certain medications can help manage symptoms, they do not cure the disease. The only possible cure is a type of stem cell transplant, but finding a suitable donor can be challenging. This trial is exploring a new method called haploidentical stem cell transplantation, which uses a related donor who is only partially matched. The researchers hope this approach will improve treatment outcomes for patients with MF.

To participate in the trial, individuals must have myelofibrosis and not have a fully matched sibling or unrelated donor, but they need to have a haploidentical donor available. Interested participants should also be able to provide informed consent and be in a condition that allows them to cooperate with the study. Unfortunately, those with active infections, very poor health, or a life expectancy of less than 30 days cannot be included. Participants in the trial can expect to receive the new treatment and will be closely monitored for its effectiveness and any side effects. This study aims to find a better way to help patients with myelofibrosis and potentially offer them a cure.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Primary disease type: Myelofibrosis (including primary myelofibrosis and myelofibrosis secondary to polycythemia vera or essential thrombocythemia).
• • No matched sibling donor or unrelated donor, with the availability of a haploidentical donor.
• • Signed informed consent.
• Exclusion Criteria:
• • 1. Active infection
• • 2. Very poor performance status (ECOG score \> 2)
• • 3. Estimated survival time \< 30 days
• • 4. Patient or family unable to cooperate
• • 5. Considered unsuitable after discussion